Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review

References

• Gallagher C J, Gregory W M, Jones A E, Stansfeld A G, Richards M A, Dhaliwal H S, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–1510
   PubMed Web of Science ®Google Scholar
• Liu Q, Fayad L, Cabanillas F, Hagemeister F B, Ayers G D, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582–1589
   PubMed Web of Science ®Google Scholar
• Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 15: 3817–3823
   Web of Science ®Google Scholar
• Freedman A S, Gribben J G, Neuberg D, Mauch P, Soiffer R J, Anderson K C, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780–2786
   PubMed Web of Science ®Google Scholar
• Cao T M, Horning S, Negrin R S, Hu W W, Johnston L J, Taylor T L, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7: 294–301
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540–2544
   PubMed Web of Science ®Google Scholar
• Brice P, Simon D, Bouabdallah R, Belanger C, Haioun C, Thieblemont C, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000; 11: 1585–1590
   PubMed Web of Science ®Google Scholar
• Schouten H C, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson H E, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927
   PubMed Web of Science ®Google Scholar
• Brown J R, Feng Y, Gribben J G, Neuberg D, Fisher D C, Mauch P, et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13: 1057–1065
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Estes J, Zasadny K R, Francis I R, Ross C W, Tuck M, et al. Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–1266
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Zelenetz A D, Press O W, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918–3928
   PubMed Web of Science ®Google Scholar
• Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
   PubMed Web of Science ®Google Scholar
• Witzig T E, Flinn I W, Gordon L I, Emmanouilides C, Czuczman M S, Saleh M N, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
   PubMed Web of Science ®Google Scholar
• Gordon L I, Molina A, Witzig T, Emmanouilides C, Raubitschek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: long-term follow-up of a phase I/II study. Blood 2004; 103: 4429–4431
   PubMed Web of Science ®Google Scholar
• Davies A J, Rohatiner A Z, Howell S, Britton K E, Owens S E, Micallef I N, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1469–1479
   PubMed Web of Science ®Google Scholar
• Fisher R I, Kaminski M S, Wahl R L, Knox S J, Zelenetz A D, Vose J M, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565–7573
   PubMed Web of Science ®Google Scholar
• Buchegger F, Antonescu C, Delaloye A B, Helg C, Kovacsovics T, Kosinski M, et al. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 2006; 94: 1770–1776
   PubMed Web of Science ®Google Scholar
• Witzig T E, Molina A, Gordon L I, Emmanouilides C, Schilder R J, Flinn I W, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90. Cancer 2007; 109: 1804–1810
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005; 16: 786–792
   PubMed Web of Science ®Google Scholar
• Vose J M, Bierman P J, Loberiza F R, Jr, Bociek R G, Matso D, Armitage J O. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007; 48: 683–690
   PubMed Web of Science ®Google Scholar
• Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Tuck M, Estes J, Kolstad A, Ross C W, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441–449
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Estes J, Zasadny K R, Francis I R, Ross C W, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–1266
   PubMed Web of Science ®Google Scholar
• Jacobs S A, Vidnovic N, Joyce J, McCook B, Torok F, Avril N. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005; 11: 7146s–7150s
   PubMed Web of Science ®Google Scholar
• Peyrade F, Italiano A, Fontana X, Peyrottes I, Thyss A. Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment. Lancet Oncol 2007; 8: 849–850
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Emmanouilides C, Darif M, Witzig T E, Gordon L I, Revell S, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007; 25: 4285–4292
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Tani M, Fanti S, Stefoni V, Musuraca G, Vitolo U, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by 90Y-labelled ibritumomab tiuxetan for patients with previously untreated indolent, nonfollicular, non-Hodgkin Lymphoma. Cancer 2008; 112: 856–862
   PubMed Web of Science ®Google Scholar